KHUE Vu NGUYEN

Dr. KHUE Vu NGUYEN


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in AIMS Neuroscience
Verified
Journal Article
Open access
PDF file
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN
Several pathophysiological functions of the human β-amyloid precursor protein (APP) have been recently proposed in different human diseases such as neurodevelopmental and neurodegenerative disorders including rare diseases such as autism, fragile X syndrome, amyotrophic lateral sclerosis, multiple sclerosis, Lesch-Nyhan disease; common and complex disorders such as Alzheimer’s disease; metabolic disorders such as diabetes; and also cancer. APP as well as all of its proteolytic fragments including the amyloid-β (Aβ) peptide, are part of normal physiology. The targeting of the components of APP proteolytic processing as a pharmacologic strategy will not be without consequences. Recent research results highlight the impact of alternative splicing (AS) process on human disease, and may provide new directions for the research on the impact of the human APP on human diseases. The identification of molecules capable of correcting and/or inhibiting pathological splicing events is therefore an important issue for future therapeutic approaches. To this end, the defective APP-mRNA isoform responsible for the disease in cells and tissues appears as an ideal target for epigenetic therapeutic intervention and antisense drugs are potential treatment.

25 February 2015 in BioMolecular Concepts
Verified
Journal Article
Open access
PDF file
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN
Beta-amyloid precursor protein (APP) is a membrane-spanning protein with a large extracellular domain and a much smaller intracellular domain. APP plays a central role in Alzheimer’s disease (AD) pathogenesis: APP processing generates β-amyloid (Aβ) peptides, which are deposited as amyloid plaques in the brains of AD individuals; point mutations and duplications of APP are causal for a subset of early-onset familial AD (FAD) (onset age 65 years old), and the pathophysiology of this disorder is not yet fully understood. APP is an extremely complex molecule that may be functionally important in its full-length configuration, as well as the source of numerous fragments with varying effects on neural function, yet the normal function of APP remains largely unknown. This article provides an overview of our current understanding of APP, including its structure, expression patterns, proteolytic processing and putative functions. Importantly, and for the first time, my recent data concerning its epigenetic regulation, especially in alternative APP pre-mRNA splicing and in the control of genomic rearrangements of the APP gene, are also reported. These findings may provide new directions for investigating the role of APP in neuropathology associated with a deficiency in the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGprt) found in patients with Lesch-Nyhan syndrome (LNS) and its attenuated variants (LNVs). Also, these findings may be of significance for research in neurodevelopmental and neurodegenerative disorders in which the APP gene is involved in the pathogenesis of diseases such as autism, fragile X syndrome (FXS) and AD, with its diversity and complexity, SAD in particular. Accurate quantification of various APP-mRNA isoforms in brain tissues is needed, and antisense drugs are potential treatments.

1 April 2014 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN

1 August 2012 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN
RNRobert K. Naviaux
Robert K. Naviaux
KPKacie K. Paik
Kacie K. Paik
WNWilliam L. Nyhan
William L. Nyhan

1 March 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN
WNWilliam L. Nyhan
William L. Nyhan

1 June 2011 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
KNKHUE Vu NGUYEN
KHUE Vu NGUYEN
RNRobert K. Naviaux
Robert K. Naviaux
KPKacie K. Paik
Kacie K. Paik
WNWilliam L. Nyhan
William L. Nyhan
Inherited mutation of a purine salvage enzyme, hypoxanthine guanine phosphoribosyltransferase (HPRT), gives rise to Lesch-Nyhan Syndrome (LNS) or HPRT-related gout. Here, we report five novel independent mutations in the coding region of the HPRT gene from five unrelated male patients manifesting different clinical phenotypes associated with LNS: exon 2: c.133A > G, p.45R > G; c.35A > C, p.12D > A; c.88delG; exon 7: c.530A > T, p.177D > V; and c.318 + 1G > C: IVS3 + 1G > C splice site mutation.